Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat

It has been reported that the major cause of mortality in diabetes is cardiovascular diseases and contribution of hypertension is significant in this context. Pioglitazone, a thiazolidinedione class of therapeutic agent is used to treat type 2 diabetes mellitus. Telmisartan, an angiotensin recepto...

Full description

Bibliographic Details
Main Authors:	Sengupta, Pinaki, Das, Arindam, Ibrahim, Fuzianna, Mandal, Uttam Kumar, Chatterjee, Bappaditya, , Syed Mahmood, Das, Sreemoy Kanti, Kifayatullah, Muhammad
Format:	Article
Language:	English English
Published:	Elsevier 2016
Subjects:	RS Pharmacy and materia medica
Online Access:	http://irep.iium.edu.my/52030/ http://irep.iium.edu.my/52030/ http://irep.iium.edu.my/52030/ http://irep.iium.edu.my/52030/1/Toxicity_Pio%20Tel_Pinaki%20paper.pdf http://irep.iium.edu.my/52030/7/52030-Safety%20profiling%20of%20pioglitazone%20and%20telmisartan%20combination%20by%20sub-chronic%20toxicity%20study%20in%20rat_SCOPUS.pdf

id	iium-52030
recordtype	eprints
spelling	iium-520302016-12-29T06:47:38Z http://irep.iium.edu.my/52030/ Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat Sengupta, Pinaki Das, Arindam Ibrahim, Fuzianna Mandal, Uttam Kumar Chatterjee, Bappaditya , Syed Mahmood Das, Sreemoy Kanti Kifayatullah, Muhammad RS Pharmacy and materia medica It has been reported that the major cause of mortality in diabetes is cardiovascular diseases and contribution of hypertension is significant in this context. Pioglitazone, a thiazolidinedione class of therapeutic agent is used to treat type 2 diabetes mellitus. Telmisartan, an angiotensin receptor blocker antihypertensive has been reported to have beneficial effect if co-administered with pioglitazone for the management of diabetes complications. The present research work aims to evaluate the safety/toxicity profile of this combination in rat model. The investigation was carried out after co-administering the drugs to the rats for 28 days at three dose levels of 50, 100 and 150 mg/kg covering low to high dose ranges. Various hematological and biochemical parameters were studied in addition to the histopathology of the major organs in order to evaluate the toxicity profile of the combination. Absence of mortality and histopathological changes as well as unaltered hematological and biochemical parameters was observed. This preliminary investigation concludes that the combination of pioglitazone and telmisartan can primarily be stated as safe in animals, even at the dose level which is several folds higher than the intended human dose. Thus, this combination can be explored in future to develop a rational therapy regimen to treat hypertensive diabetic patients. Elsevier 2016-11 Article PeerReviewed application/pdf en http://irep.iium.edu.my/52030/1/Toxicity_Pio%20Tel_Pinaki%20paper.pdf application/pdf en http://irep.iium.edu.my/52030/7/52030-Safety%20profiling%20of%20pioglitazone%20and%20telmisartan%20combination%20by%20sub-chronic%20toxicity%20study%20in%20rat_SCOPUS.pdf Sengupta, Pinaki and Das, Arindam and Ibrahim, Fuzianna and Mandal, Uttam Kumar and Chatterjee, Bappaditya and , Syed Mahmood and Das, Sreemoy Kanti and Kifayatullah, Muhammad (2016) Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat. Regulatory Toxicology and Pharmacology, 81. pp. 155-161. E-ISSN 0273-2300 http://www.journals.elsevier.com/regulatory-toxicology-and-pharmacology/ 10.1016/j.yrtph.2016.08.009
repository_type	Digital Repository
institution_category	Local University
institution	International Islamic University Malaysia
building	IIUM Repository
collection	Online Access
language	English English
topic	RS Pharmacy and materia medica
spellingShingle	RS Pharmacy and materia medica Sengupta, Pinaki Das, Arindam Ibrahim, Fuzianna Mandal, Uttam Kumar Chatterjee, Bappaditya , Syed Mahmood Das, Sreemoy Kanti Kifayatullah, Muhammad Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat
description	It has been reported that the major cause of mortality in diabetes is cardiovascular diseases and contribution of hypertension is significant in this context. Pioglitazone, a thiazolidinedione class of therapeutic agent is used to treat type 2 diabetes mellitus. Telmisartan, an angiotensin receptor blocker antihypertensive has been reported to have beneficial effect if co-administered with pioglitazone for the management of diabetes complications. The present research work aims to evaluate the safety/toxicity profile of this combination in rat model. The investigation was carried out after co-administering the drugs to the rats for 28 days at three dose levels of 50, 100 and 150 mg/kg covering low to high dose ranges. Various hematological and biochemical parameters were studied in addition to the histopathology of the major organs in order to evaluate the toxicity profile of the combination. Absence of mortality and histopathological changes as well as unaltered hematological and biochemical parameters was observed. This preliminary investigation concludes that the combination of pioglitazone and telmisartan can primarily be stated as safe in animals, even at the dose level which is several folds higher than the intended human dose. Thus, this combination can be explored in future to develop a rational therapy regimen to treat hypertensive diabetic patients.
format	Article
author	Sengupta, Pinaki Das, Arindam Ibrahim, Fuzianna Mandal, Uttam Kumar Chatterjee, Bappaditya , Syed Mahmood Das, Sreemoy Kanti Kifayatullah, Muhammad
author_facet	Sengupta, Pinaki Das, Arindam Ibrahim, Fuzianna Mandal, Uttam Kumar Chatterjee, Bappaditya , Syed Mahmood Das, Sreemoy Kanti Kifayatullah, Muhammad
author_sort	Sengupta, Pinaki
title	Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat
title_short	Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat
title_full	Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat
title_fullStr	Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat
title_full_unstemmed	Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat
title_sort	safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat
publisher	Elsevier
publishDate	2016
url	http://irep.iium.edu.my/52030/ http://irep.iium.edu.my/52030/ http://irep.iium.edu.my/52030/ http://irep.iium.edu.my/52030/1/Toxicity_Pio%20Tel_Pinaki%20paper.pdf http://irep.iium.edu.my/52030/7/52030-Safety%20profiling%20of%20pioglitazone%20and%20telmisartan%20combination%20by%20sub-chronic%20toxicity%20study%20in%20rat_SCOPUS.pdf
first_indexed	2023-09-18T21:13:46Z
last_indexed	2023-09-18T21:13:46Z
_version_	1777411425990344704

Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat

Similar Items